Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Safety and Efficacy of Tisagenlecleucel in Primary CNS Lymphoma: A phase I/II clinical trial
Blood 2022 Feb 15;[EPub Ahead of Print], MJ Frigault, J Dietrich, KME Gallagher, MJ Roschewski, JT Jordan, D Forst, SR Plotkin, D Cook, KS Casey, KA Lindell, GD DePinho, K Katsis, EL Elder, M Leick, BD Choi, N Horick, F Preffer, M Saylor, S McAfee, PV O'Donnell, TR Spitzer, BR Dey, Z DeFilipp, A El-Jawahri, TT Batchelor, MV Maus, YB ChenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.